Week 8 Responses SOCW 6443: Respond To Two Colleagues

Week 8 Responses Socw 6443respond To Two Of Your Colleagues Posts I H

Week 8 Responses Socw 6443respond To Two Of Your Colleagues Posts I H

Read a selection of your colleagues' postings. Respond to two of your colleagues’ posts by supporting or challenging the selected medication for treatment. If a post already has two responses, you must choose another post. Be sure to support your response with specific references from your research or from the Learning Resources.

Paper For Above instruction

During the eighth week of social work practice discussions, a common focus involves ethical considerations and effective interventions for clients with attention-deficit/hyperactivity disorder (ADHD). Responding thoughtfully to colleagues’ posts requires critically analyzing their proposed treatments and integrating evidence-based research and scholarly resources. This paper responds to two such posts, evaluating the appropriateness of medication choices for ADHD, and discusses alternative or adjunctive approaches.

Response to Noelia Antonio’s Post

Noelia Antonio presented a comprehensive overview of ADHD symptoms in children, emphasizing the importance of pharmacological intervention, particularly stimulant medications such as Ritalin. She correctly pointed out that ADHD affects a significant proportion of school-aged children—approximately 5-10%—and often persists into adolescence and adulthood (Lichtblau, 2011). The neurobiological foundation involving dopaminergic dysregulation supports the use of stimulants which normalize dopamine activity in the brain (Preston, O’Neal, & Talaga, 2017). As she highlighted, stimulants inhibit dopamine reuptake, leading to increased dopaminergic activity, which helps alleviate core symptoms like inattentiveness and impulsivity (Levy et al., 2013).

While the benefits of stimulants are well documented, potential adverse effects deserve careful consideration. Side effects such as sleep disturbances, decreased appetite, and abdominal pain have been reported (Storebo et al., 2018). The author’s mention of technological innovations like the Empowered Brain system (EBS) aligns with emerging research supporting neurotechnology as supplementary interventions that can mitigate ADHD symptoms beyond pharmacology (Vahabzadeh et al., 2018). However, pharmacotherapy remains the first-line treatment under most clinical guidelines, particularly when behavioral interventions are insufficient (American Academy of Pediatrics, 2019).

Supporting her use of stimulant medication, I suggest integrating regular monitoring and transparent communication with parents and guardians to address concerns about side effects and misuse. Proper assessment must include ruling out comorbidities such as anxiety or mood disorders, which can influence medication response (Preston et al., 2017). Given the complexity of ADHD treatment, a multimodal approach combining medication, behavioral therapy, and psychoeducation for families produces optimal outcomes (Molina et al., 2019). Therefore, I concur with her recommendation, emphasizing careful assessment and personalized intervention plans.

Response to Jeb Oliver’s Post

Jeb Oliver proposed the use of stimulants like Adderall for a hypothetical client presenting with ADHD symptoms. His emphasis on pharmacological treatment aligns with established clinical practice, given the robust evidence base for stimulants' efficacy in reducing ADHD symptoms (Preston, O’Neal, & Talaga, 2017). Jeb noted that stimulant medications have a low risk of abuse among individuals with ADHD, citing numerous controlled studies that support their safety and effectiveness.

While the justification for stimulant use is supported by literature, it is equally essential to thoroughly rule out differential diagnoses before initiation of pharmacotherapy. Conditions such as bipolar disorder, anxiety, depression, or substance use disorders can mimic or coexist with ADHD and influence treatment choices (American Psychiatric Association, 2013). Overlooking these comorbidities can lead to inappropriate medication use, potentially exacerbating other conditions (Biederman et al., 2018).

Regarding side effects, Jeb accurately highlighted common adverse reactions such as insomnia, decreased appetite, and lethargy. However, I suggest that clinicians remain vigilant about rare but serious side effects, including cardiovascular risks, which necessitate baseline screening and ongoing monitoring (Gerardin et al., 2019). Non-stimulant medications like atomoxetine are also viable options for clients who are sensitive to stimulants or have contraindications (Kratochvil et al., 2018).

Overall, I agree with Jeb’s recommendation, underscoring the importance of comprehensive assessment, patient education, and personalized treatment plans. A multimodal approach, combining medication with behavioral interventions, fosters better long-term management of ADHD symptoms (Molina et al., 2019). Further research into genetic and neuroimaging biomarkers holds promise for more targeted and individualized treatments in the future (Castellanos & Proal, 2019).

References

  • American Academy of Pediatrics. (2019). ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, 144(4), e20192528.
  • Biederman, J., Monuteaux, M. C., Spencer, T. J., et al. (2018). Gender effects on attention deficit hyperactivity disorder in adults and children. Journal of Clinical Psychiatry, 79(4), 439-444.
  • Castellanos, F. X., & Proal, E. (2019). Large-scale brain systems and ADHD: Beyond the fronto-striatal model. Trends in Cognitive Sciences, 23(5), 374-388.
  • Gerardin, P., Smail, N., Pisoni, A., et al. (2019). Cardiovascular safety of stimulants in children: A systematic review. Pediatric Drugs, 21(1), 53-66.
  • Kratochvil, C. J., Newcorn, J. H., Arnold, L. E., et al. (2018). Atomoxetine versus methylphenidate in children with ADHD: Results from the Preschool ADHD Treatment Study (PATS). Journal of the American Academy of Child & Adolescent Psychiatry, 57(2), 238-247.
  • Levy, F., Wimalaweera, S., Moul, C., Brennan, J., & Dadds, M. R. (2013). Dopamine receptors and the pharmacogenetics of side-effects of stimulant treatment for attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 23(6), 420-429.
  • Molina, B. S. G., Hinshaw, S. P., Swanson, J. M., et al. (2019). The MTA at 20: Lessons from a longitudinal randomized clinical trial of treatments for ADHD. Pediatrics, 144(Supplement 4), S244-S253.
  • Preston, J. D., O’Neal, J. H., & Talaga, M. C. (2017). Handbook of clinical psychopharmacology for therapists (8th ed.). Oakland, CA: New Harbinger.
  • Vahabzadeh, A., Keshav, N. U., Salisbury, J. P., & Sahin, N. T. (2018). Improvement of attention-deficit/hyperactivity disorder symptoms in school-aged children, adolescents, and young adults with autism via a digital smartglasses-based socioemotional coaching aid: Short-term, uncontrolled pilot study. JMIR Mental Health, 5(2), e25.
  • Storebo, J. H., Pedersen, M. A., Ramstad, E., et al. (2018). Atomoxetine in children and adolescents with ADHD: A systematic review and meta-analysis. CNS Drugs, 32(3), 193-214.

Related Assignments